Skip to content

Overview

For more information, please contact us.

For more information, please contact us.

Established in 2003 by Prof. Raymond Kaempfer and Dr. Gila Arad from the faculty of medicine at the Hebrew University, Atox Bio is a late stage biotechnology company that develops novel immunomodulators for critically ill patients.
Reltecimod, Atox Bio’s lead product, is initially being developed to treat Necrotizing Soft Tissue Infections (NSTI), a rare, life threatening infection for which no therapy currently exists.
Atox Bio recently completed enrollment of the ACCUTE (Reltecimod Clinical Composite endpoint StUdy in necrotizing soft Tissue InfEctions) study, a phase 3 clinical trial evaluating the efficacy of Reltecimod in patients with NSTI. Results of the study are expected to be presented at a medical meeting in the first half of 2020. Previously, the company completed a phase 2 study of Reltecimod in NSTI. Results demonstrated that patients treated with Reltecimod had a meaningful improvement across multiple end points.
Reltecimod is also being studied in REAKT (Reltecimod Efficacy for Acute Kidney Injury Trial), in patients with abdominal sepsis induced Acute Kidney Injury (SA-AKI). Interim results from the REAKT study are expected in the first half of 2020.
Reltecimod was granted Fast Track status for both NSTI and AKI and Orphan Drug designation from the FDA for NSTI as well as Orphan Medicinal Product designation from the European Commission for NSTI.
Reltecimod development is supported by a contract from BARDA (Biomedical Advanced Research and Development Authority).